CONGENITAL FIBROSARCOMA

This adverse event was reported 3 times

CONGENITAL FIBROSARCOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 LAROTRECTINIB 1 0.0011
1 NIRSEVIMAB 1 0.0006
2 DACTINOMYCIN 1 0.0005
3 SIROLIMUS 1 0.0001
4 IFOSFAMIDE FOR INJECTION 1 0.0000
5 DOXORUBICIN HYDROCHLORIDE 1 0.0000
6 ETOPOSIDE 1 0.0000
7 DOXORUBICIN 1 0.0000
8 CYCLOPHOSPHAMIDE FOR INJECTION 1 0.0000
9 CYCLOPHOSPHAMIDE 1 0.0000
See all drugs enriched for association with CONGENITAL FIBROSARCOMA

CONGENITAL FIBROSARCOMA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] 1 0.0006
1 Actinomycin [EPC] 1 0.0005
2 Topoisomerase Inhibitor [EPC] 1 0.0000
3 Alkylating Drug [EPC] 1 0.0000
4 Kinase Inhibitor [EPC] 2 0.0000
5 Corticosteroid [EPC] 1 0.0000
See all drug classes enriched for association with CONGENITAL FIBROSARCOMA